MetaCap

Adagene (ADAG) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adagene (ADAG) has outperformed Spruce Biosciences (SPRB) over the past year, losing 2.2% versus a loss of 63.8%. Over five years, ADAG leads with a -79.7% price change compared with -99.8% for SPRB. Adagene is the larger company by market cap ($118.2 million vs $109.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%SPRB-63.81%
+177%+51%-75%
Nov 21, 20251 yearNov 20, 2026
ADAG-81.97%SPRB-99.77%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus SPRB key metrics
MetricADAGSPRB
Share price$1.76$38.00
Market cap$118.17M$109.21M
1-day change-12.44%-6.15%
YTD return-6.88%-56.38%
1-year return-2.22%-63.81%
5-year return-79.75%-99.75%
Forward P/E—11.79
EPS (TTM)$-0.37$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M$0
Revenue growth (YoY)+7332.76%-100.00%
Net income (latest FY)$-17.61M$-38.97M
Operating margin-279.48%—
Net margin-229.56%—
52-week high$4.85$111.00
52-week low$1.27$38.00
Distance from 52-week high-63.71%-65.77%
Analyst consensusnonestrong_buy
Avg. price target upside+463.07%+288.00%
Average volume348.81K89.33K
Shares outstanding67.14M2.87M
Employees12825
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADAG has outperformed SPRB by 61.6 percentage points over the past year.
  • Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -100.00%).

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

ADAG vs SPRB FAQ

Which is bigger, Adagene or Spruce Biosciences?

Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $109.21M for Spruce Biosciences (SPRB).

Which stock has performed better over the past year, ADAG or SPRB?

ADAG returned -2.22% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons